The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...
Drug Pricing Strategy
Regeneron Priced Otarmeni at Zero — And That’s the Most Expensive Move in Ultra-Rare Disease This Decade
Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...
Novo Nordisk’s Hims & Hers Deal Isn’t a Distribution Play — It’s a Controlled Burn of Its Own Pricing Floor
Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...